According to TipRanks.com, Raffat has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.3% and a 45.1% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Teva Pharmaceutical, and Arcus Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amylyx Pharmaceuticals Inc with a $35.50 average price target, an 117.0% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $35.00 price target.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMLX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Read More on AMLX: